LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development of molecular diagnostic tests for cancer, presented several pre-clinical studies at the American Association for Cancer Research (AACR) 2008 Annual Meeting in San Diego, April 12-16. Kathleen Danenberg, CEO and President of Response Genetics, Inc., co-presented several studies that highlight the gene expression technology and its role in identifying predictive markers in several types of cancer, including colorectal, pancreatic, and liver metastasis.
